Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372929
IPSCIO Record ID: 370599
MAPK (mitogen-activated protein kinase) pathway is a central axis driving aberrant proliferation in a broad spectrum of cancers.
IPSCIO Record ID: 365586
IPSCIO Record ID: 276397
A clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
IPSCIO Record ID: 366038
IPSCIO Record ID: 282869
Licensee shall have, with respect to such designated Optioned Compound and its associated Products, for no further consideration, a sole and exclusive license, including the right to grant sub-licenses, under the Licensor Patent Rights, and a nonexclusive license to use the Licensor Know-How, in each case solely to make, use, offer for sale, sell and import such product in the Territory for use outside the Field, except that such licenses shall exclude Specifically Excluded Areas.
Product means any and all products for use in the Field that include, in whole or as a component thereof, an Optioned Compound.
Patents are related, but not limited to, Treatment of Human Prostate Disease, and, Method of treating Hematologic Tumors and Cancers.
Optioned Compounds means the Primary Compound, the Clinical Candidates and, if Licensee makes the payment required, then also the Potential Optioned Compounds.
Backup Compound means, as of the Option Exercise, any analog of the Primary Compound and any other compound developed by Licensor that has been screened for regulation of the E2F1 protein prior to the Effective Date or as part of the Strategic Alliance, and as a direct result of such screening has been determined to modulate E2F1 in cancer cells, directly leading to apoptosis.
Specifically Excluded Areas means the protection or treatment of normal cells against all forms of radiation including ionizing and non-ionizing radiation (including but not limited to radiotherapy), including protection of normal cells against cancer induced by any form of radiation, and the use of a compound in stents.
IPSCIO Record ID: 1054
Its intended use is as a means of micro-arterial brachytherapy in the treatment of soft tissue cancer tumors in the liver. Soft tissue tumors are connected to the blood supply and this kind of therapy is administered through the blood supply system. Soft tissue tumors are among the most difficult forms of cancer to treat.
IPSCIO Record ID: 25940
The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.
i) interstitially within a cancerous tumour;
ii) into a resection cavity after surgical removal of a cancerous tumour;
iii) into the peritoneal cavity; or
iv) via the vasculature ( to the extent it becomes technically feasible).